Search bioRxivSearch

Biology subjects

Balaskas, K.

Publications and source records attributed to Balaskas, K..

3 recordsLinked to original sources

Feasibility of Automated Deep Learning Design for Medical Image Classification by Healthcare Professionals with Limited Coding Experience

Deep learning has huge potential to transform healthcare. However, significant expertise is required to train such models and this is a significant blocker for their translation into clinical practice. In this study, we therefore sought to evaluate the use of automated deep learning software to develop medical image diagnostic classifiers by healthcare professionals with limited coding - and no deep learning - expertise.\n\nWe used five publicly available open-source datasets: (i) retinal fundus images (MESSIDOR); (ii) optical coherence tomography (OCT) images (Guangzhou Medical University/Shiley Eye Institute, Version 3); (iii) images of skin lesions (Human against Machine (HAM)10000) and (iv) both paediatric and adult chest X-ray (CXR) images (Guangzhou Medical University/Shiley Eye Institute, Version 3 and the National Institute of Health (NIH)14 dataset respectively) to separately feed into a neural architecture search framework that automatically developed a deep learning architecture to classify common diseases. Sensitivity (recall), specificity and positive predictive value (precision) were used to evaluate the diagnostic properties of the models. The discriminative performance was assessed using the area under the precision recall curve (AUPRC). In the case of the deep learning model developed on a subset of the HAM10000 dataset, we performed external validation using the Edinburgh Dermofit Library dataset.\n\nDiagnostic properties and discriminative performance from internal validations were high in the binary classification tasks (range: sensitivity of 73.3-97.0%, specificity of 67-100% and AUPRC of 0.87-1). In the multiple classification tasks, the diagnostic properties ranged from 38-100% for sensitivity and 67-100% for specificity. The discriminative performance in terms of AUPRC ranged from 0.57 to 1 in the five automated deep learning models. In an external validation using the Edinburgh Dermofit Library dataset, the automated deep learning model showed an AUPRC of 0.47, with a sensitivity of 49% and a positive predictive value of 52%. The quality of the open-access datasets used in this study (including the lack of information about patient flow and demographics) and the absence of measurement for precision, such as confidence intervals, constituted the major limitation of this study.\n\nAll models, except for the automated deep learning model trained on the multi-label classification task of the NIH CXR14 dataset, showed comparable discriminative performance and diagnostic properties to state-of-the-art performing deep learning algorithms. The performance in the external validation study was low. The availability of automated deep learning may become a cornerstone for the democratization of sophisticated algorithmic modelling in healthcare as it allows the derivation of classification models without requiring a deep understanding of the mathematical, statistical and programming principles. Future studies should compare several application programming interfaces on thoroughly curated datasets.

bioinformatics

The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular Degeneration

Background/AimsNeovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on fellow eyes have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement.\n\nMethodsRetrospective, electronic medical record database study of the Moorfields AMD database of 8174 eyes/120,756 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 413 nonsequential, and 1110 unilateral eyes.\n\nResultsMean VA of sequentially treated fellow eyes at baseline was significantly higher (62{+/-}13), VA gain over two years lower (0.65{+/-}14), and proportion of eyes with good VA ([≥]20/40 or 70 letters) higher (46%) than the respective first eyes (baseline VA 54{+/-}16, VA gain at two years 5.6{+/-}15, percentage of eyes with good VA 38%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27-147) weeks.\n\nConclusionThis reports shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years of treatment.\n\nPRECISDepending on age, fellow eye involvement occurs in 32% of patients with neovascular AMD by two years. Fellow eyes generally maintain better vision, except in cases where late-stage disease in the first eye was untreated.

epidemiology

One and Two Year Visual Outcomes from the Moorfields AMD Database - an Open Science Resource for the Study of Neovascular Age-related Macular Degeneration

ObjectivesTo analyse treatment outcomes and share clinical data from a large, single-center, well-curated database (8174 eyes / 6664 patients with 120,756 single entries) of patients with neovascular age related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (VEGF). By making our depersonalised raw data openly available, we aim to stimulate further research in AMD, as well as setting a precedent for future work in this area.\n\nSettingRetrospective, comparative, non-randomised electronic medical record (EMR) database cohort study of the UK Moorfields AMD database with data extracted between 2008 and 2018.\n\nParticipants3357 eyes/patients (61% female). Extraction criteria were [≥] 1 ranibizumab or aflibercept injection, entry of \"AMD\" in the diagnosis field of the EMR, and a minimum of one year of follow-up. Exclusion criteria were unknown date of first injection and treatment outside of routine clinical care at Moorfields before the first recorded injection in the database.\n\nMain outcome measuresPrimary outcome measure was change in VA at one and two years from baseline as measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Secondary outcomes were the number of injections and predictive factors for VA gain.\n\nResultsMean VA gain at one-year and two years were +5.5{+/-}0.5 and +4.9{+/-}0.68 letters respectively. Fifty-four percent of eyes gained [≥]5 letters at two years, 63% had stable VA ({+/-}[≤]14 letters), forty-four percent of eyes maintained good VA ([≥]70 letters). Patients received a mean of 7.7{+/-}0.06 injections during year one and 13.0{+/-}0.2 injections over two years.\n\nYounger age, lower baseline VA, and more injections were associated with higher VA gain at two years.\n\nConclusionThis study benchmarks high quality EMR study results of real life AMD treatment and promotes open science in clinical AMD research by making the underlying data publicly available.\n\nStrengths and limitations of this study- Large sample size, retrospective, single centre, electronic medical record database study\n- High quality real life data\n- Open science approach with sharing of depersonalised raw data

epidemiology